Cardiogen (20mg)
Cardiogen is a synthetic cardiovascular bioregulatory tetrapeptide (AEDR: Ala‑Glu‑Asp‑Arg) studied for its cellular reparative and cardioprotective properties. Preclinical research indicates it enters cells and modulates fundamental survival pathways, supporting cytoskeletal integrity and reducing apoptosis in stressed cardiac tissue. This protocol outlines a once-daily subcutaneous approach.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Cardiogen functions as a bioregulator of gene expression at the cellular and nuclear level. Research shows it upregulates structural proteins (actin, tubulin, vimentin, nuclear lamins), supporting cytoskeletal integrity and nuclear function. This mechanism promotes cellular repair and reduces programmed cell death in stressed or damaged tissue. In rodent studies, daily Cardiogen administration reduced post-myocardial infarction mortality ~3-fold, preserved cardiac tissue architecture, and maintained higher glycogen stores.
Quick Start
- Reconstitution: Add 3.0 mL of bacteriostatic water → ~6.67 mg/mL concentration.
- Typical Daily Range: 200–500 mcg once daily (gradual titration over 8–16 weeks).
- Storage: Lyophilized: freeze at −20 °C; post-reconstitution, refrigerate at 2–8 °C; avoid freeze-thaw cycles.
Typical / Gradual Approach (3 mL = ~6.67 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 200 mcg | 3 Units (0.03 mL) |
| Weeks 3–4 | 300 mcg | 4.5 Units (0.04 mL) |
| Week 5 | 400 mcg | 6 Units (0.06 mL) |
| Weeks 6–12 | 500 mcg | 7.5 Units (0.07 mL) |
Studies report administration once daily subcutaneously.
Related compounds
Reconstitution Steps
- Draw up 3.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial; avoid foaming.
- Gently swirl/rotate until dissolved (do not shake vigorously).
- Date and refrigerate at 2–8 °C, protected from light.
Protocol Overview
- Objective: Support cellular repair mechanisms and cardiovascular resilience in research models.
- Schedule: Daily subcutaneous injections for 8–12 weeks (extendable to 16).
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze-thaw.
Dosing Protocol
- Initiation: 200 mcg daily for 2 weeks; increase by ~100 mcg every 1–2 weeks.
- Target: 400–500 mcg daily by weeks 5–12.
- Frequency: Once daily (subcutaneously).
- Cycle Duration: 8–12 weeks; optionally extendable to 16.
- Timing: Any consistent time; rotate sites daily.
- Break between cycles: Post-cycle (10–20 days), a washout period of 3–6 months is recommended before a new cycle. Khavinson bioregulatory peptides have a prolonged effect on gene expression—typically 2–3 cycles/year are performed.
Washout & Cycle Restart
When can I restart?
Post-cycle (10–20 days), a washout period of 3–6 months is recommended before a new cycle. Khavinson bioregulatory peptides have a prolonged effect on gene expression—typically 2–3 cycles/year are performed.
Minimum wait period: 12 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions.
- Reconstituted: Refrigerate at 2–8 °C for up to 2–4 weeks with bacteriostatic water; avoid freeze-thaw.
- Allow vials to reach room temperature before opening.
Important Notes
Potential Benefits & Side Effects
Potential Benefits:
- Cardioprotective effects in rodent models of myocardial infarction, reducing mortality and necrotic tissue.
- Stimulation of cardiomyocyte and fibroblast proliferation, reducing pathological fibrosis.
- Selective dual action: protecting healthy cells while promoting apoptosis in neoplastic cells.
- Preservation of cardiac tissue metabolic function (glycogen, mitochondrial integrity).
- No human clinical data available; all evidence is from laboratory/animal research.
- Generally well-tolerated in preclinical models; mild injection site reactions possible.
Potential Side Effects:
- Mild injection site reactions (redness, itching).
- Transient fatigue or 'flu-like' feeling (rare).
- Limited human data (Khavinson bioregulatory peptide).
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Khavinson bioregulator — limited evidence
Only small-sample Russian studies. No peer-reviewed RCTs or pharmacokinetic data in Western journals. Long-term safety unclear.
📄 Khavinson VK — Bull Exp Biol Med 2003References
- MDPI Cells Journal (2023) — The Senescence-Associated Secretory Phenotype (SASP) of the Cardiovascular System and Its Peptide Regulation
View Source - MDPI Int J Mol Sci — Peptide Regulation of Gene Expression: Cardiovascular Bioregulators
View Source - PubMed (2012) — Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates the expression of cytoskeletal proteins
View Source - PubMed (2009) — Antineoplastic effect of Cardiogen on sarcoma M-1 in aged mice
View Source - PubMed (2016) — Peptide bioregulators: experimental and clinical studies of geroprotectors
View Source
Recommended Supplements
Multivitamin (High-quality)
External Sources & Regulatory Status
Regulatory Approvals
Кардиоген® · Cardiovascular bioregulation (2007)
Approved in Russia (Khavinson bioregulator)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →